Cosmos Health's C-Sept PRO Product Poised for $1.3M Annual Sales, 72% Gross Margin
COSM is trading near its 52-week low of $0.183 (12% above the low).
Summary
Cosmos Health's C-Sept PRO antiseptic solution is gaining significant traction in Greek hospitals, with annualized sales projected to exceed $1.3 million at a high 72% gross margin. This new revenue stream is material for the company, which recently reported going concern warnings, widened losses, and increased cash burn in its Q1 2026 10-Q filing. The high-margin sales from C-Sept PRO could help address the company's financial challenges and contribute to its ambitious 2026-2029 financial guidance.
At the time of this announcement, COSM was trading at $0.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7M. The 52-week trading range was $0.18 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.